Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust and King’s Health Partners, London, UK.
Emerg Med J. 2010 Nov;27(11):829-33. doi: 10.1136/emj.2009.085027. Epub 2010 Jun 7.
To test, by completion of a simple questionnaire, patient knowledge of whether 15 commonly used over-the-counter and prescription analgesics and cough/cold remedies contained paracetamol and patient knowledge of the 4 g maximum daily dose of paracetamol.
Patients in the emergency department triage waiting area of a busy London teaching hospital were asked to complete a standardised one-page questionnaire. From a list of 15 commonly used over-the-counter and prescription products, patients were asked which contained paracetamol, responding 'yes', 'no' or 'not sure' for each. They were also asked to state the recommended maximum daily dose of paracetamol.
910 patients were enrolled in the study (mean age 39 years, 53% women). The mean±SD score was 6.5±2.5. The maximum score was 14 (n=2) and the minimum score was 0 (n=11). For the recommended maximum daily dose, 93.7% (n=853) of patients gave an answer. Of these, 53.8% answered correctly, 4.7% quoted a supratherapeutic dose and 41.5% a subtherapeutic dose.
Patient knowledge of paracetamol-containing products and of the maximum daily dose is currently insufficient to ensure safe use of the drug. Interventions are required to address these knowledge gaps to prevent unintentional repeated supratherapeutic ingestion of paracetamol. These interventions could include targeted public education and/or appropriate and effective medication labelling.
通过完成一份简单的问卷,测试患者是否了解 15 种常用的非处方和处方止痛药和咳嗽/感冒药中是否含有对乙酰氨基酚,以及是否了解对乙酰氨基酚的 4 g 日最大剂量。
在伦敦一所繁忙教学医院的急诊分诊等候区,要求患者填写一份标准化的一页问卷。从 15 种常用的非处方和处方产品列表中,患者被要求回答每个产品是否含有对乙酰氨基酚,回答“是”、“否”或“不确定”。他们还被要求说明对乙酰氨基酚的推荐最大日剂量。
共有 910 名患者参与了这项研究(平均年龄 39 岁,53%为女性)。平均±SD 得分为 6.5±2.5。最高得分为 14(n=2),最低得分为 0(n=11)。对于推荐的最大日剂量,93.7%(n=853)的患者给出了答案。其中,53.8%的答案正确,4.7%的答案给出了治疗剂量,41.5%的答案给出了治疗剂量。
目前,患者对含对乙酰氨基酚产品和最大日剂量的知识不足以确保药物的安全使用。需要采取干预措施来解决这些知识差距,以防止意外重复摄入超治疗剂量的对乙酰氨基酚。这些干预措施可以包括有针对性的公众教育和/或适当和有效的药物标签。